J&J's Janssen pharma group is chipping in $5 million for Stand Up To Cancer's health equity push in clinical trials. (Credit: Shutterstock)
June 17, 2022 11:41 AM EDTUpdated 05:19 PM
Pharma
Marketing

J&J inks clin­i­cal tri­al deal with Stand Up To Can­cer, lat­est phar­ma to join can­cer non­prof­it study ef­forts

Beth Snyder Bulik

Senior Editor

John­son & John­son’s new deal with a lead­ing can­cer or­ga­ni­za­tion aims to boost di­ver­si­ty in ear­ly phase clin­i­cal tri­als. The $5 mil­lion spon­sor­ship agree­ment be­tween …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times